Search

Displaying results 1791 - 1800 of 10000 in total
  1. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. … The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine.

  2. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist. … It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.

  3. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  4. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.

    Synonyms: 6-hydroxymethylacylfulvene
  5. Drug

    Perflubron

    go.drugbank.com/drugs/DB05791
    Investigational

    Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. … GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase.

  7. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  8. Drug

    HGTV-43

    go.drugbank.com/drugs/DB05807
    Experimental

    HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc. … HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection.

  9. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    [L54773,L54768] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability … Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol, 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
  10. Drug

    NBI-6024

    go.drugbank.com/drugs/DB05819
    Investigational

    NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.